Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism CDK7 inhibitors(Cyclin-dependent kinase 7 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC23H26F3N6OP |
InChIKeyJDJOUBVVSQDIRC-AWEZNQCLSA-N |
CAS Registry2417302-07-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 1 | Denmark | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Germany | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Canada | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Taiwan Province | 22 Oct 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 23 Jan 2020 | |
Hormone receptor positive breast cancer | Phase 1 | United States | 23 Jan 2020 | |
Human epidermal growth factor 2 negative carcinoma of breast | Phase 1 | United States | 23 Jan 2020 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 23 Jan 2020 | |
PIK3CA mutation/HR-positive/HER2-negative Breast Cancer | Phase 1 | United States | 23 Jan 2020 | |
Small Cell Lung Cancer | Phase 1 | United States | 23 Jan 2020 |
Phase 1 | Hormone receptor positive HER2 negative breast cancer HR positive | HER2 Negative | 14 | (sgihubvlow) = enpilsdmgv ecdjwpdsoa (hoonrxznyy ) View more | Positive | 31 May 2023 | ||
Phase 1 | 87 | (SLIs) | - | Positive | 26 May 2023 | ||
gemcitabine+SY-5609 (SLIs) | (bfjcpnxing) = rbtbrsckzx jauomdieia (papmqeueep ) | ||||||
Phase 1 | - | (fpczwpmmrp) = zmsoqmnmzi dznkugqgap (zswitgmhnr ) | - | 02 Jun 2022 | |||
Phase 1 | 51 | (noghurrici) = (≥20%) included nausea, diarrhea, fatigue, decreased appetite, and thrombocytopenia; majority were low grade (1/2) and reversible klcoukoahd (vcjxctrvpt ) | Positive | 20 Sep 2021 |